Back to Browse Journals » Journal of Asthma and Allergy » Volume 4

Clinical update on the use of biomarkers of airway inflammation in the management of asthma

Authors Wadsworth SJ, Sin DD, Dorscheid DR

Published Date June 2011 Volume 2011:4 Pages 77—86

DOI http://dx.doi.org/10.2147/JAA.S15081

Published 30 June 2011

SJ Wadsworth1,2, DD Sin1,2, DR Dorscheid1,2
1UBC James Hogg Research Centre, Providence Heart and Lung Institute, St Paul's Hospital, Vancouver, Canada; 2Department of Medicine, University of British Columbia, British Columbia, Canada

Abstract: Biological markers are already used in the diagnosis and treatment of cardiovascular disease and cancer. Biomarkers have great potential use in the clinic as a noninvasive means to make more accurate diagnoses, monitor disease progression, and create personalized treatment regimes. Asthma is a heterogeneous disease with several different phenotypes, generally triggered by multiple gene-environment interactions. Pulmonary function tests are most often used objectively to confirm the diagnosis. However, airflow obstruction can be variable and thus missed using spirometry. Furthermore, lung function measurements may not reflect the precise underlying pathological processes responsible for different phenotypes. Inhaled corticosteroids and ß2-agonists have been the mainstay of asthma therapy for over 30 years, but the heterogeneity of the disease means not all asthmatics respond to the same treatment. High costs and undesired side effects of drugs also drive the need for better targeted treatment of asthma. Biomarkers have the potential to indicate an individual's disease phenotype and thereby guide clinicians in their decisions regarding treatment. This review focuses on biomarkers of airway inflammation which may help us to identify, monitor, and guide treatment of asthmatics. We discuss biomarkers obtained from multiple physiological sources, including sputum, exhaled gases, exhaled breath condensate, serum, and urine. We discuss the inherent limitations and benefits of using biomarkers in a heterogeneous disease such as asthma. We also discuss how we may modify our study designs to improve the identification and potential use of potential biomarkers in asthma.

Keywords: asthma, inflammation, airway biomarkers, urinary biomarkers, serum biomarkers

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Oxidative stress and antibacterial properties of a graphene oxide-cystamine nanohybrid

Nanda SS, An SS, Yi DK

International Journal of Nanomedicine 2015, 10:549-556

Published Date: 12 January 2015

Effects of magnetic cobalt ferrite nanoparticles on biological and artificial lipid membranes

Drašler B, Drobne D, Novak S, Valant J, Boljte S, Otrin L, Rappolt M, Sartori B, Iglič A, Kralj-Iglič V, Šuštar V, Makovec D, Gyergyek S, Hočevar M, Godec M, Zupanc J

International Journal of Nanomedicine 2014, 9:1559-1581

Published Date: 27 March 2014

Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]

Bosani M, Ardizzone S, Porro GB

Biologics: Targets and Therapy 2014, 8:39-40

Published Date: 31 January 2014

Clinical utility of asthma biomarkers: from bench to bedside

Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Biologics: Targets and Therapy 2013, 7:199-210

Published Date: 29 August 2013

Newer agents for Helicobacter pylori eradication

Fiorini G, Zullo A, Gatta L, Castelli V, Ricci C, Cassol F, Vaira D

Clinical and Experimental Gastroenterology 2012, 5:109-112

Published Date: 18 June 2012

Corrigendum

Nelson DA, Ruf A, Oaknin J, Burgansky-Eliash Z, Barash H, Izhaky D, Loewenstein A, Barak A, Bartov E, Rock T, Grinvald A

Clinical Ophthalmology 2011, 5:1317-1318

Published Date: 15 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign)

Eric Chen, David M Brown, Matthew S Benz, et al

Clinical Ophthalmology 2010, 4:1151-1158

Published Date: 6 October 2010

Current trends in drug treatment of obsessive–compulsive disorder

Eric H Decloedt, Dan J Stein

Neuropsychiatric Disease and Treatment 2010, 6:233-242

Published Date: 10 May 2010